Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display genomic instability. Its lead product, TeloView SMM, is a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. The TeloView SMM assay has a potential total addressable market of over 500,000 tests per year.


TSXV:TELO - Post by User

Telo Genomics Corp > Webinar $TELO CEO Kris Weinberg Nov 21st @ 1PM ET / 10AM PT
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(49)
•••
Post by bmreedon Nov 17, 2023 5:29pm
123 Views
Post# 35742011

Webinar $TELO CEO Kris Weinberg Nov 21st @ 1PM ET / 10AM PT

Webinar $TELO CEO Kris Weinberg Nov 21st @ 1PM ET / 10AM PT

Live Webinar - Telo Genomics Corp $TELO w/ CEO Kris Weinberg

Tuesday, November 21st at 1PM ET / 10AM PT

Q&A with Radius Research 

Register Here - https://us02web.zoom.us/webinar/register/4017001560718/WN_kYeDpBRLRu6wQv1WPfdMHQ

 

CEO Kris Weinberg will provide a company overview and outline the 2024 commercialization plans along with upcoming catalysts.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities